AstraZeneca PLC Director/PDMR Shareholding (9148N)
May 26 2020 - 5:30AM
UK Regulatory
TIDMAZN
RNS Number : 9148N
AstraZeneca PLC
26 May 2020
26 May 2020 10:30 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 21 May 2020,
Pascal Soriot, Chief Executive Officer, was granted an award of the
Company's ordinary shares of $0.25 each (Ordinary Shares) under the
terms of the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
PDMR Ordinary Shares Award price per
granted under Ordinary Share
the AZPSP
Pascal Soriot 8,734 GBP73.76
---------------- ----------------
This award forms part of the AZPSP award granted to Mr Soriot on
6 March 2020 and has been made to take account of the revised
limits for the AZPSP approved by shareholders at the Company's 2020
Annual General Meeting. As such, it is subject to a combination of
performance measures focused on scientific, commercial and
financial performance assessed over a three-year performance period
(1 January 2020 to 31 December 2022). The Ordinary Shares granted
under the AZPSP are subject to a two-year holding period following
the performance period, and are due to vest on the fifth
anniversary of grant.
Details of the performance measures attached to the AZPSP award
can be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2019, which is
available on the Company's website at
www.astrazeneca.com/annualreport2019.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Pascal Soriot
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
---------------------------- -------------------------------------
b) Nature of the transaction Grant of a share award under the
AstraZeneca Performance Share Plan
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP73.76 8,734
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 21 May 2020
---------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------- -------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUNUBRRRUVURR
(END) Dow Jones Newswires
May 26, 2020 05:30 ET (09:30 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024